ArticleEmerging Company ProfileAug 30, 2024
Nvelop: Delivering gene editors to specific cells via virus-like particles
Propelled by $100M in seed funding, Cambridge, Mass.-based biotech is developing dual virus-like particle platforms from two gene editing pioneers